Next 10 |
home / stock / mnpr / mnpr articles
WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharma company focused on devel...
The Dow Jones index closed higher by around 575 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern a...
WILMETTE, Ill., May 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharmaceutical company focused o...
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS...
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index jumping more than 100 points on Friday. The Dow traded up 0.36% t...
U.S. stocks traded higher this morning, with the Dow Jones index jumping more than 150 points on Friday. Following the market opening Friday, the D...
U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping more than 400 points on Thursday. The Dow traded up 1.13% to ...
Shares of Etsy, Inc. (NASDAQ: ETSY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial result...
Monopar Therapeutics Inc (NASDAQ:MNPR) shares jumped during the trading session on Thursday on a strong volume session volume of 16.179 millio...
News, Short Squeeze, Breakout and More Instantly...
Monopar Therapeutics Inc. Company Name:
MNPR Stock Symbol:
NASDAQ Market:
Monopar Therapeutics Inc. Website:
WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled “Evaluation of Anti-uPAR Antibody as a Radiopharmaceuti...
Highlights: Builds on Companies’ respective core strengths Aligns intellectual property rights Establishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar’s development and potential future commercial programs WILMETTE, ...
WILMETTE, Ill., June 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the preclinical development of its novel first-in-class lead...